Spruce Biosciences (SPRB) Current Deferred Revenue (2023 - 2024)
Spruce Biosciences (SPRB) posted quarterly Current Deferred Revenue of $700000.0 for Q3 2024, down 91.03% year-over-year from $7.8 million in Q4 2023, and down 46.07% quarter-over-quarter from $1.3 million in Q2 2024.
Spruce Biosciences (SPRB) Current Deferred Revenue (2023 - 2024) Analysis & Trends
Spruce Biosciences (SPRB) has reported Current Deferred Revenue for 2 consecutive years, with $700000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Current Deferred Revenue fell 91.03% year-over-year to $700000.0; the TTM figure through Sep 2024 stood at $700000.0 (down 91.03% YoY), while the FY2023 annual figure was $4.9 million, changed N/A from the prior year.
- Current Deferred Revenue retreated to $700000.0 in Q3 2024 per SPRB's latest filing, from $1.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $9.2 million in Q1 2023 and bottomed at $700000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 2.90 Mn |
| Dec 31, 2023 | 4.91 Mn |
| Sep 30, 2023 | 7.80 Mn |
| Jun 30, 2023 | 8.06 Mn |
| Mar 31, 2023 | 9.20 Mn |